Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Squamous Cell Carcinoma of Head and Neck 38Nasopharyngeal Carcinoma 27Lung Neoplasms 26Biliary Tract Neoplasms 24Uterine Cervical Neoplasms 23Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 19Cholangiocarcinoma 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 14Ovarian Neoplasms 14Neoplasms 14Neoplasm Metastasis 13Esophageal Neoplasms 13Colorectal Neoplasms 12Carcinoma 12Stomach Neoplasms 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Carcinoma, Transitional Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Recurrence 6Pancreatic Neoplasms 6Nasopharyngeal Neoplasms 5Gallbladder Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5

Interventions

Radiotherapy 2tislelizumab 1pembrolizumab 1TP protocol 1Paclitaxel 1Lomustine 1Cisplatin 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Recurrence, Local × Cisplatin × Clear all
NCT06942416 2025-04-24

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
36 enrolled
Gynecologic

Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡